These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32299818)

  • 1. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
    Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
    Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
    Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
    Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
    Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
    Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
    Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
    Tan B; Khattak A; Felip E; Kelly K; Rich P; Wang D; Helwig C; Dussault I; Ojalvo LS; Isambert N
    Target Oncol; 2021 Jul; 16(4):435-446. PubMed ID: 34009501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
    Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
    Doi T; Fujiwara Y; Koyama T; Ikeda M; Helwig C; Watanabe M; Vugmeyster Y; Kudo M
    Oncologist; 2020 Sep; 25(9):e1292-e1302. PubMed ID: 32324927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
    Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
    Paz-Ares L; Kim TM; Vicente D; Felip E; Lee DH; Lee KH; Lin CC; Flor MJ; Di Nicola M; Alvarez RM; Dussault I; Helwig C; Ojalvo LS; Gulley JL; Cho BC
    J Thorac Oncol; 2020 Jul; 15(7):1210-1222. PubMed ID: 32173464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
    Oaknin A; Ghamande SA; Kasamatsu Y; Gil-Martin M; Grau-Bejar JF; Garcia-Duran C; Sato M; Siddiqui A; Chaudhary SP; Vugmeyster Y; Hasegawa K
    Clin Cancer Res; 2024 Mar; 30(5):975-983. PubMed ID: 38165683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1.
    Vugmeyster Y; Wilkins J; Koenig A; El Bawab S; Dussault I; Ojalvo LS; De Banerjee S; Klopp-Schulze L; Khandelwal A
    Clin Pharmacol Ther; 2020 Sep; 108(3):566-574. PubMed ID: 31955412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
    Strauss J; Heery CR; Schlom J; Madan RA; Cao L; Kang Z; Lamping E; Marté JL; Donahue RN; Grenga I; Cordes L; Christensen O; Mahnke L; Helwig C; Gulley JL
    Clin Cancer Res; 2018 Mar; 24(6):1287-1295. PubMed ID: 29298798
    [No Abstract]   [Full Text] [Related]  

  • 13. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
    Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
    Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of
    Spira A; Awada A; Isambert N; Lorente D; Penel N; Zhang Y; Ojalvo LS; Hicking C; Rolfe PA; Ihling C; Dussault I; Locke G; Borel C
    Front Oncol; 2022; 12():981940. PubMed ID: 36568239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
    Chung HC; Arkenau HT; Lee J; Rha SY; Oh DY; Wyrwicz L; Kang YK; Lee KW; Infante JR; Lee SS; Kemeny M; Keilholz U; Melichar B; Mita A; Plummer R; Smith D; Gelb AB; Xiong H; Hong J; Chand V; Safran H
    J Immunother Cancer; 2019 Feb; 7(1):30. PubMed ID: 30717797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
    Cho BC; Lee JS; Wu YL; Cicin I; Dols MC; Ahn MJ; Cuppens K; Veillon R; Nadal E; Dias JM; Martin C; Reck M; Garon EB; Felip E; Paz-Ares L; Mornex F; Vokes EE; Adjei AA; Robinson C; Sato M; Vugmeyster Y; Machl A; Audhuy F; Chaudhary S; Barlesi F
    J Thorac Oncol; 2023 Dec; 18(12):1731-1742. PubMed ID: 37597750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
    Khasraw M; Weller M; Lorente D; Kolibaba K; Lee CK; Gedye C; I de La Fuente M; Vicente D; Reardon DA; Gan HK; Scott AM; Dussault I; Helwig C; Ojalvo LS; Gourmelon C; Groves M
    Neurooncol Adv; 2021; 3(1):vdab058. PubMed ID: 34056607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials.
    Ni X; Xing Y; Sun X; Suo J
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):211-222. PubMed ID: 31208922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.
    Birrer M; Li G; Yunokawa M; Lee JY; Kim BG; Oppermann CP; Zhou Q; Nishio S; Okamoto A; Wu X; Mileshkin L; Oaknin A; Ray-Coquard I; Hasegawa K; Jehl G; Vugmeyster Y; Zhang S; Bajars M; Yonemori K
    JAMA Oncol; 2024 Sep; 10(9):1204-1211. PubMed ID: 39052242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
    Gameiro SR; Strauss J; Gulley JL; Schlom J
    Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.